当前位置:首页 - 行情中心 - 康泰生物(300601) - 财务分析 - 现金流量表

康泰生物

(300601)

  

流通市值:116.69亿  总市值:144.75亿
流通股本:9.00亿   总股本:11.17亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,931,909,390.241,187,721,487.72498,322,841.572,869,059,868.95
  收到其他与经营活动有关的现金63,067,024.5856,853,372.7443,623,746.28124,817,870.3
  经营活动现金流入小计1,994,976,414.821,244,574,860.46541,946,587.852,993,877,739.25
  购买商品、接受劳务支付的现金334,903,461.78219,576,510.13113,540,886.07403,960,940.95
  支付给职工以及为职工支付的现金381,873,815.76263,462,966.97125,610,047.61501,429,663.51
  支付的各项税费78,886,181.0775,457,696.1144,061,413.72125,526,448.68
  支付其他与经营活动有关的现金947,594,373.6661,373,737.96358,010,138.781,327,391,400.75
  经营活动现金流出小计1,743,257,832.211,219,870,911.17641,222,486.182,358,308,453.89
  经营活动产生的现金流量净额251,718,582.6124,703,949.29-99,275,898.33635,569,285.36
二、投资活动产生的现金流量:
  收回投资收到的现金2,520,425,248.11,396,400,000614,000,0004,202,800,000
  取得投资收益收到的现金52,370,769.9737,319,704.9722,401,308.45195,606,986.98
  处置固定资产、无形资产和其他长期资产收回的现金净额388,400355,650350,000304,225
  投资活动现金流入小计2,573,184,418.071,434,075,354.97636,751,308.454,398,711,211.98
  购建固定资产、无形资产和其他长期资产支付的现金312,278,105.07185,229,595.55130,390,235.51331,922,832.18
  投资支付的现金2,378,000,0001,155,000,000470,000,0004,550,800,001
  支付其他与投资活动有关的现金--59,317.3-
  投资活动现金流出小计2,690,278,105.071,340,229,595.55600,449,552.814,882,722,833.18
  投资活动产生的现金流量净额-117,093,68793,845,759.4236,301,755.64-484,011,621.2
三、筹资活动产生的现金流量:
  吸收投资收到的现金25,250,00024,000,000--
  其中:子公司吸收少数股东投资收到的现金25,250,00024,000,000--
  取得借款收到的现金11,000,00011,000,00011,000,00039,900,000
  收到其他与筹资活动有关的现金00-11,765,606.11
  筹资活动现金流入小计36,250,00035,000,00011,000,00051,665,606.11
  偿还债务支付的现金0--262,991,749.54
  分配股利、利润或偿付利息支付的现金75,199,860.8139,127,778.087,091.94131,552,215.86
  支付其他与筹资活动有关的现金113,512.56113,512.56113,512.561,929,856.32
  筹资活动现金流出小计75,313,373.3739,241,290.64120,604.5396,473,821.72
  筹资活动产生的现金流量净额-39,063,373.37-4,241,290.6410,879,395.5-344,808,215.61
四、汇率变动对现金及现金等价物的影响-2,626,481.9-1,888,707.34-1,325,405.62-959,185.16
五、现金及现金等价物净增加额92,935,040.34112,419,710.73-53,420,152.81-194,209,736.61
  加:期初现金及现金等价物余额221,859,517.84221,859,517.84221,859,517.84416,069,254.45
  期末现金及现金等价物余额314,794,558.18334,279,228.57168,439,365.03221,859,517.84
补充资料:
  净利润-47,718,308.42-70,273,947.22
  资产减值准备-36,573,694.81-133,831,177.41
  固定资产和投资性房地产折旧-192,112,323.57-357,915,157
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-192,112,323.57-357,915,157
  无形资产摊销-23,017,332.54-42,445,592.57
  长期待摊费用摊销-13,096,536.12-33,020,003.17
  处置固定资产、无形资产和其他长期资产的损失--5,694.37-934,468.51
  固定资产报废损失-2,074,660.62-8,670,029.39
  公允价值变动损失--14,820,920.85--5,288,602.78
  财务费用-47,102,764.23-45,694,881.47
  投资损失--1,501,526.56--1,509,002.51
  递延所得税--6,401,851.06--24,809,822.75
  其中:递延所得税资产减少--8,112,208.54-8,136,199.37
    递延所得税负债增加-1,710,357.48--32,946,022.12
  存货的减少--41,898,625.88-49,176,851.48
  经营性应收项目的减少--195,584,721.41-159,186,275.04
  经营性应付项目的增加--103,914,517.39--276,354,777.12
  现金的期末余额-334,279,228.57-221,859,517.84
  减:现金的期初余额-221,859,517.84-416,069,254.45
  现金及现金等价物的净增加额-112,419,710.73--194,209,736.61
公告日期2026-10-272026-08-222026-04-222026-04-22
审计意见(境内)标准无保留意见
TOP↑